Pulmonary Hypertension – Landscape & Forecast – Disease Landscape & Forecast

Pulmonary hypertension (PH) is a devastating disease with high levels of morbidity and mortality and no cure. Despite the rarity of the disease, the potential commercial opportunities for drugs approved for PH are considerable, driven by premium pricing and the likelihood of polypharmacy. Although this market has become congested, commercial interest in PH remains high owing to the need for more-efficacious and disease-modifying agents, as well as the lack of approved treatment options for unserved populations.

Questions answered

  • Novel agents such as Merck & Co.’s sotatercept, United Therapeutics’ ralinepag, and Gossamer Bio’s seralutinib are in late-phase development for PH. What do interviewed thought leaders say about the advantages and disadvantages of these therapies? How will the launch of these agents affect prescribing decisions?
  • Generic formulations have launched for several key branded therapies in recent years. How have these launches influenced prescribing patterns? What effect have generic launches had on entrenched brands, and what will be their impact on the performance of emerging therapies?
  • A large unmet need exists for the treatment of PH WHO groups 2, 3, and 5. What are the other key unmet needs in PH? How likely are these unmet needs to be fulfilled during the forecast period?
  • Patients with pulmonary arterial hypertension are typically prescribed PDE-5 inhibitors and/or ERAs as first-line therapy. What are the prescribing considerations dictating physician preferences for later-line treatments, and how do they vary between countries/geographical regions?

Content highlights

Geographies: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Key drugs covered: Uptravi, Orenitram, Adempas, Opsumit, Adcirca, Tracleer, Revatio, Letairis / Volibris, Remodulin, Flolan, Veletri, Tyvaso, Ventavis, Beraprost, ralinepag, Yutrepia, Tyvaso DPI, sotatercept, seralutinib, macitentan / tadalafil FDC.

Key companies mentioned: Johnson & Johnson, United Therapeutics, Bayer HealthCare, GlaxoSmithKline, Gilead Sciences, Pfizer, MannKind Corporation, Merck & Co., Liquidia Technologies, Gossamer Bio.

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution enhancement

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Table of contents

launch Related Market Assessment Reports